In addition, we designed a SLC25A22-targeting VNP system for in vivo siRNA delivery37, and showed that it potentiates anti-PD1 efficacy in KRAS-mutant CRC by rejuvenating cytotoxic CD8+ T cells in tumor microenvironment. Here, SLC25A22 is linked to neoplasm.